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NEED FOR THE STUDY 
We are today witnessing an epidemic of diabetes mellitus(DM), globally 
nationally. DM and its complications have become the most important 
contemporary and challenging health problem. There are 170 million diabetics 
worldwide. In india more than 5 crores have been affected. India has become 
the diabetic capital of world. 
Practically every system is affected by complications of DM .Attention 
is usually paid to micro and macro angiopathy,retinopathy and nephropathy,but 
one of the system most neglected in DM is the respiratory system,except for 
the recognition of increased infection prevalence like tuberculosis. 
Normal lung function has three components,which contribute to gas exchange  
• Ventilation – Movements of gas in and out of lung. 
• Perfusion – The perfusion of venous blood from right ventricle to 
ventilated alveoli. 
• Diffusion – The diffusion of gases across the alveolar capillary 
membrane. 
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Ventilation has two processes Inspiration and Expiration. Inspiration is 
an active process occurring on contraction of intercostal muscles and 
diaphragm normally, Expiration is essentially passive due to elastic recoil of 
chest wall and lungs. 
Several changes occur in DM, including: 
1. Non-enzymatic glycosylation of connective tissue,especially 
collagen,which might be responsible for end organ damage causing 
diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and lung 
changes. (diabetic pulmonopathy)  
2. Diabetic myopathy 
3. Micro vascular angiopathy 
These changes could lead to 
 Loss of elasticity. 
 Altered perfusion characteristics. 
 Weakness of the respiratory muscles responsible for ventilation. 
Ventilation may be affected by myopathy and altered elastic recoil of 
lung tissue. Perfusion may be affected by changes in basement membrane and 
micro vascular angiopathy. 
All may contribute to altered lung function, there are studies, which 
showed changes in lung function in DM, but the study number is not large. 
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This study will help add to the growing literature on changes in lung function 
in diabetes mellitus. 
There is  increasing interest in this area and few publications. However 
the total number of studies with respect to lung function in type 2 DM is still 
very small and involved very small patients. Hence this study was performed to 
add to the experience in this area. 
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INTRODUCTION 
Diabetes mellitus is a heterogeneous group of metabolic disorders 
characterized by chronic hyperglycemia resulting from defects in insulin 
secretion, action or both. Based on etiopathogenic categories, it is classified as 
Type-1 and Type-2 diabetes mellitus. In Type-1 there is absolute deficiency of 
insulin secretion. In Type-2 there is a combination of  resistance to insulin 
action and inadequate compensatory insulin secretory response. Diabetes 
mellitus is accompanied by wide spread biochemical, morphological and 
functional abnormalities which may precipitate certain complications that 
affect the renal, cardio-vascular, neural systems and also skin, liver, collagen 
and elastic fibres. Thus diabetes is a multisystem disorder that affect many 
organs of the body.
[1] 
 
ADA-Criteria for the Diagnosis of Diabetes Mellitus.
[2] 
 
• Symptoms of diabetes plus random blood glucose concentration -11.1 
mmol/L (200 mg/dL)aor 
• Fasting plasma glucose -7.0 mmol/L (126 mg/dL)bor  
• Two-hour plasma glucose -11.1 mmol/L (200 mg/dL) during an oral 
glucose tolerance testc 
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TYPE 2 DIABETES MELLITUS 
                  Type 2 diabetes is characterized by the combination of peripheral 
insulin resistance and inadequate insulin secretion by pancreatic beta cells. 
Insulin resistance, which has been attributed to elevated levels of free fatty 
acids in plasma,
[3]  leads to decreased glucose transport into muscle cells, 
elevated hepatic glucose production, and increased breakdown of fat. 
Fig 1: Mechanism of hyperglycemia in type 2 DM 
 
For type 2 diabetes mellitus to occur, both defects must exist. For example, all 
overweight individuals have insulin resistance, but diabetes develops only in 
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those who cannot increase insulin secretion sufficiently to compensate for their 
insulin resistance. Their insulin concentrations may be high, yet 
inappropriately low for the level of glycemia. 
          Beta cell dysfunction is a major factor across the spectrum of pre-
diabetes to diabetes. A study of obese adolescents by Bacha et al confirms what 
is increasingly being stressed in adults as well: Beta cell function happens early 
in the pathological process and does not necessarily follow stage of insulin 
resistance. 
[4]  Singular focus on insulin resistance as the "be all and end all" is 
gradually shifting, and hopefully better treatment options that focus on the beta 
cell pathology will emerge to treat the disorder early. 
            In the progression from normal glucose tolerance to abnormal glucose 
tolerance, postprandial blood glucose levels increase first; eventually, fasting 
hyperglycemia develops as suppression of hepatic gluconeogenesis fails. 
         During the induction of insulin resistance, such as is seen after high-
calorie diet, steroid administration, or physical inactivity, increased glucagon 
levels and increased glucose-dependent insulinotropic polypeptide (GIP) levels 
accompany glucose intolerance; however, postprandial glucagonlike peptide-1 
(GLP-1) response is unaltered.
[5] This has physiologic implications; for 
example, if the GLP-1 level is unaltered, GLP-1 may be a target of therapy in 
now a days. 
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 Major risk factors for type 2 diabetes mellitus are the following: 
• Age greater than 45 years (though, as noted above, type 2 diabetes mellitus is 
occurring with increasing frequency in young individuals) 
• Weight greater than 120% of desirable body weight 
• Family history of type 2 diabetes in a first-degree relative (eg, parent or 
sibling) 
• Hispanic, Native American, African American, Asian American, or Pacific 
Islander descent 
• History of previous impaired glucose tolerance (IGT) or impaired fasting 
glucose (IFG) 
• Hypertension  (>140/90 mm Hg) or dyslipidemia (high-density lipoprotein 
[HDL] cholesterol level < 40 mg/dL or triglyceride level >150 mg/dL) .
[8] 
  
• History of gestational diabetes mellitus or of delivering a baby with a birth 
weight of >9 lb 
• Polycystic ovarian syndrome (which results in insulin resistance) 
            Type 2 DM has a strong genetic component. The concordance of type 2 
DM in identical twins is between 70 and 90%. Individuals with a parent with 
type 2 DM have an increased risk of diabetes; if both parents have type 2 DM, 
the risk approaches 40%.  Insulin resistance, as demonstrated by reduced 
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glucose utilization in skeletal muscle, is present in many nondiabetic, first-
degree relatives of individuals with type 2 DM. The disease is polygenic and 
multifactorial since in addition to genetic susceptibility, environmental factors 
(such as obesity, nutrition, and physical activity) modulate the phenotype. The 
genes that predispose to type 2 DM are incompletely identified, but recent 
genome-wide association studies have identified several genes that convey a 
relatively small risk for type 2 DM (relative risk of 1.1-1.5). 
        Most prominent is a variant of the transcription factor 7-like 2 (TCF7L2)  
gene that has been associated with type 2 diabetes in several populations and 
with impaired glucose tolerance in one population at high risk for diabetes. 
TCF7L2 is a transcription factor and key component of the Wnt signaling 
pathway, and it is involved in the development of a wide variety of cell 
lineages and organs. 
[9]  Potential mechanisms through which TCF7L2 variants 
influence type 2 diabetes include its role in adipogenesis, myogenesis, and 
pancreatic islet development, as well as in beta-cell survival and insulin 
secretory granule function.
[10,11]  It is also involved in the transcriptional 
regulation of the genes for proglucagon and the glucagon-like peptides GLP-1 
and GLP-2; these peptides play a role in postprandial insulin secretion. 
[12]                        
                 Finally, TCF7L2 polymorphisms have been associated with impaired 
insulin secretion, glucose production, and glucose tolerance via direct effects 
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on pancreatic islet beta cells.
[13,14]  Indeed, dysregulation of glucose 
metabolism, decreased processing of proinsulin, and elevated levels of gastric 
inhibitory peptide and glycated haemoglobin (HbA1c) can be observed in 
normoglycemic individuals with  TCF7L2 polymorphisms before the onset of 
type 2 diabetes.
[15,16]
  Thus, while the specific mechanism driving the 
development of type 2 diabetes remains unclear, there is sufficient evidence to 
demonstrate that TCF7L2 variants strongly predict the development of type 
2diabetes and/or the progression to diabetes from impaired glucose 
tolerance.[14, 17]  
          Although genetic tests for TCF7L2 could help predict the incidence and 
the rate of onset of type 2 diabetes,
[18]  the strongest predictors continue to be 
positive family history, increased body mass index, increased blood pressure, 
and increased serum levels of triglycerides, apolipoprotein A-1, and liver 
enzymes, all of which precede inception of metabolic syndrome.
[19]   In fact, the 
predictive power of  TCF7L2 variants disappears with lifestyle modifications 
or metformin treatment, while the improved insulin sensitivity resulting from 
these changes directly oppose the pathological influence of TCF7L2  
variants.
[20]  These data suggest that genetic susceptibility to type 2 diabetes as 
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determined by TCF7L2 variants might prove an actionable indicator for early 
intervention and disease prevention.[17] 
The incidence of Type-2 diabetes has been steadily increasing in urban 
areas to 8.4% 
 
the rapid urbanization, change in the lifestyle coupled with 
ethnic susceptibility has increased the incidence of diabetes mellitus. This 
globally important condition needs to be understood with a proper perspective 
to deliver effective strategies to the individual and also the population.               
            The chronic complications of DM affect many organ systems and are 
responsible for the majority of morbidity and mortality associated with the 
disease. Chronic complications can be divided into vascular and nonvascular 
complications . The vascular complications of DM are further subdivided into 
microvascular (retinopathy, neuropathy, nephropathy) and macrovascular 
complications [coronary artery disease (CAD), peripheral arterial disease 
(PAD), cerebrovascular disease]. Nonvascular complications include problems 
such as gastro paresis, infections, and skin changes. Long-standing diabetes 
may be associated with hearing loss.
[41]
  Whether type 2 DM in elderly 
individuals is associated with impaired mental function is not clear. 
PATHOGENESIS OF COMPLICATIONS 
              Although chronic hyperglycemia is an important etiologic factor 
leading to complications of DM, the mechanism(s) by which it leads to such 
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diverse cellular and organ dysfunction is unknown. Four prominent theories, 
which are not mutually exclusive, have been proposed to explain how 
hyperglycemia might lead to the chronic complications of DM.
 [33] 
  
        One theory is that increased intracellular glucose leads to the formation of 
advanced glycosylation end products (AGEs) via the nonenzymatic 
glycosylation of intra- and extracellular proteins. Nonenzymatic glycosylation 
results from the interaction of glucose with amino groups on proteins. AGEs 
have been shown to cross-link proteins (e.g., collagen, extracellular matrix 
proteins), accelerate atherosclerosis, promote glomerular dysfunction, reduce 
nitric oxide synthesis, induce endothelial dysfunction, and alter extracellular 
matrix composition and structure. The serum level of AGEs correlates with the 
level of glycemia, and these products accumulate as glomerular filtration rate 
declines.
[44]
 
        A second theory is based on the observation that hyperglycemia increases 
glucose metabolism via the sorbitol pathway. Intracellular glucose is 
predominantly metabolized by phosphorylation and subsequent glycolysis, but 
when increased, some glucose is converted to sorbitol by the enzyme aldose 
reductase. Increased sorbitol concentration alters redox potential, increases 
cellular osmolality, generates reactive oxygen species, and likely leads to other 
types of cellular dysfunction. However, testing of this theory in humans, using 
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aldose reductase inhibitors, has not demonstrated significant beneficial effects 
on clinical endpoints of retinopathy, neuropathy, or nephropathy. 
          Third hypothesis proposes that hyperglycemia increases the formation of 
diacylglycerol leading to activation of protein kinase C (PKC).
 [34] 
  
 Among other actions, PKC alters the transcription of genes for fibronectin, 
type IV collagen, contractile proteins, and extracellular matrix proteins in 
endothelial cells and neurons. Inhibitors of PKC are being studied in clinical 
trials. 
          And the fourth theory proposes that hyperglycemia increases the flux 
through the hexosamine pathway, which generates fructose-6-phosphate, a 
substrate for O-linked glycosylation and proteoglycan production. The 
hexosamine pathway may alter function by glycosylation of proteins such as 
endothelial nitric oxide synthase or by changes in gene expression of 
transforming growth factor (TGF-β) or plasminogen activator inhibitor-1     
(PAI - 1). 
          Growth factors appear to play an important role in DM-related 
complications, and their production is increased by most of these proposed 
pathways. Vascular endothelial growth factor A (VEGF-A) is increased locally 
in diabetic proliferative retinopathy and decreases after laser photocoagulation. 
TGF- β is increased in diabetic nephropathy and stimulates basement 
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membrane production of collagen and fibronectin by mesangial cells. Other 
growth factors, such as platelet-derived growth factor, epidermal growth factor, 
insulin-like growth factor I, growth hormone, basic fibroblast growth factor, 
and even insulin, have been suggested to play a role in DM-related 
complications.
[43]
 
           The micro vascular complications appear early, within 5 to 10yrs and 
macro vascular complications appear within 15 to 20yrs from the onset of 
diabetes. If diabetes is detected early and adequate steps are taken,it may be 
possible to significantly delay the occurrence of  complications and thereafter 
the progression. 
DIABETES AND LUNG         
         There are histopathological changes seen in lungs of diabetics such as 
thickened alveolar epithelial and pulmonary capillary basal lamina leading to 
reduced pulmonary elastic recoil and lung volume. There is impaired diffusion 
due to reduced pulmonary capillary blood volume and thickening of the 
basement membrane. The underlying mechanism seem to be microangiopathy 
brought in by the nonenzymatic glycosylation of various scleroproteins in 
lungs and elsewhere. Since collagen is the most abundant tissue protein in 
major bronchi, vessels and interstitium, the alterations in pulmonary functions 
occur as a rule. These alterations are reversible to start with & can be delayed 
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by keeping the blood sugar levels in the normal range. Similar changes have 
been observed with advancing age though progression & intensity of changes 
are less marked than seen in patients with DM .
[21]
  Non-enzymatic 
glycoslyation induced alteration of lung connective tissue is the most likely 
mechanism underlying the mechanical pulmonary dysfunction in diabetic 
subjects. This suggests that lung should also be considered as target organ. 
[22] 
 
The review of research work in this field shows two conflicting schools 
of thought, each one either expounding involvement or non-involvement of  
respiratory system in Type-2 DM. The pulmonary function in diabetes of this 
cross section of population is not extensively documented. The present study is 
undertaken to evaluate the impact of Type-2 DM and pulmonary function in 
this cross section of population and thereby resolve the conflict between two 
schools of thought.  
RESPIRATORY FUNCTION  
      The principal function of the lung is to efficiently exchange oxygen in the 
distal air spaces with carbon dioxide in the blood. Ventilation-perfusion 
matching is accomplished by structural attributes that create an enormous 
capillary surface area and exceedingly thin diffusion barrier for gas.   The 
airways, forming the connection between the outside world and the terminal 
respiratory units, are of central importance to our understanding of lung 
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function in health and disease. Intrapulmonary airways are divided into three 
major groups: bronchi, membranous bronchioles  and respiratory 
bronchioles/gasexchange ducts . Bronchi, by definition, have cartilage in their 
wall. Respiratory bronchioles serve a dual function as airways and as part of 
the alveolar volume (gas exchange).
[42]
  
           Secondary functions of the lung also are important, such as surfactant 
synthesis, secretion, and recycling, mucociliary clearance, immunomodulation, 
neuroendocrine signaling, and synthesis and secretion of a myriad of molecules 
by its epithelial and endothelial cells. The diversity of secondary functions 
emphasizes the importance of the lung in homeostasis. 
SPIROMETRY 
          Spirometry is the most basic and frequently performed pulmonary 
function test. Pulmonary function testing measures how well you are breathing. 
There are different types of breathing tests that can be done during pulmonary 
function testing. These tests include spirometry, Peak flow meter, lung 
volumes and diffusing capacity. Lung volumes measure different parts of the 
breath to determine how much air you can breathe in and out. Some of the 
volumes are: total lung capacity, vital capacity and functional residual capacity. 
The diffusing capacity of the lungs (DLCO) measures how well gases such as 
oxygen move from the lungs into the blood. 
[23,24]
 The most common way to 
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measure the DLCO is the ten second single-breath-hold technique. Spirometry 
is a simple test to measure how much (volume) and how fast (flow) you can 
move air into and out of your lungs. Spirometry is a non-invasive and 
completely painless procedure, like the measurement of blood pressure it is a 
useful screen of general health.
[42]
 
NEED FOR SPIROMETRY 
Diagnostic 
      • To evaluate symptoms, signs or abnormal laboratory tests: Symptoms: 
shortness of breath, wheezing, cough, phlegm. Signs: diminished breath 
sounds, cyanosis. 
    • To screen individuals at risk of having pulmonary disease: Smokers, 
occupational exposure 
    • Assess preoperative risk 
    • Assess prognosis (lung transplants) 
Monitoring 
    • To assess therapeutic interventions: Bronchodilator therapy Steroid 
treatment for asthmatics, interstitial lung disease, etc Management of 
congestive heart failure, Other (antibiotics in cystic fibrosis) 
17 
 
• To describe the course of diseases affecting lung function: Pulmonary 
diseases (Obstructive or interstitial diseases) Cardiac diseases (congestive heart 
failure) Neuromuscular disease 
• To monitor persons in occupations with exposure to injurious agents 
Disability/Impairment Evaluations 
• To assess patients as part of a rehabilitation program: Medical, 
Industrial,Vocational 
• To assess risks as part of an insurance evaluation 
Contraindications 
• Hemoptysis of unknown origin 
• Pneumothorax 
• Unstable cardiovascular status 
• Thoracic/abdominal/cerebral aneurysm 
• Recent thoracic surgery 
• Nausea or vomiting 
Types of Spirometers 
        Spirometers use different methods of measuring patient’s lung values. The 
most common type of device is called a “pneumotach”. This device has been 
the “gold standard” of spirometry for many years. A pneumotach measures air 
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flow where particles of gas are accelerated, creating a pressure gradient to 
measure flow and calculate a volume of gas (essentially it measures a drop 
in pressure). 
        Anemonometer, this type of flowmeter consists of a thin platinum wire, 
electrically heated to constant temperature, and centrally located in a tube. As 
gas passes through the meter the wire cools off requiring electrical energy to 
maintain its temperature. The extra electrical energy is a measure of energy. 
This system is very vulnerable to damage and needs to be handled with extra 
care. The flowmeters are also not reliable due to the inability to know the 
direction of the patient’s flow to measure inspiration and expiration. 
      Ultrasonic spirometers utilize transducers located on either side of the flow 
sensor and receive sound in alternating directions. When the gas flow moves 
through the tube, the pulse that travels against the flow is slowed down and 
takes a longer time to reach the opposite transducer. The pulse traveling with 
the flow is sped up and takes a shorter time to reach the opposite transducer. 
The gas flow in the flow sensor is then calculated from upstream and 
downstream times. This calculation is independent of gas composition, 
pressure, temperature and humidity. 
      Turbine spirometers use an infrared light to measure inspiratory and 
expiratory flows. The harder the patient blows, the faster the turbine rotates. 
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These rotations are measured by an infrared beam. They do not need to be 
calibrated or corrected for BTPS and are not influenced by pressure changes or 
air temperature. 
Flow Volume Loop 
        The Flow Volume Loop is the most important curve in spirometry. It 
shows the relationship between flow (how fast air moves) and volume (how big 
of a breath). The normal flow volume is the graphic display of the FVC and is 
used to evaluate the patient’s effort and test technique. A normal flow volume 
loop starts with a hard expiration to the peak expiratory flow (PEF). After the 
PEF the patient’s flow decreases as more air is expired.
 [46] 
 The Forced 
Expiratory Flow (FEF 25) measures the point were 25% of the volume is 
expired. The (FEF 50) and (FEF 75) are where 50% and 75% of the volume is 
expired. The (FEF 25-75) is the mean flow between the FEF 25 and FEF 75. 
This measurement is used in the diagnoses of many respiratory diseases. 
(A) Normal. Inspiratory limb of loop is symmetric and convex. Expiratory 
limb is linear. Flow rates at the midpoint of the inspiratory and 
expiratory capacity are often measured. Maximal inspiratory flow at 
50% of forced vital capacity (MIF 50%FVC) is greater than maximal 
expiratory flow at 50% FVC (MEF 50%FVC) because dynamic 
compression of the airways occurs during exhalation. 
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Fig 2: Normal flow-volume loop of spirometry 
                                  
(B) Obstructive disease (eg, emphysema, asthma). Although all flow rates 
are diminished, expiratory prolongation predominates, and MEF < MIF. 
Peak expiratory flow is sometimes used to estimate degree of airway  
obstruction but is dependent on patient effort.
 [50]
                         
           Fig 3:Flow-volume loop (Obstructive pattern)      
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         Fig 4: Flow-volume loop (Restrictive pattern) 
 
(C) Restrictive disease (eg, interstitial lung disease, kyphoscoliosis). The 
loop is narrowed because of diminished lung volumes, but the shape is  
generally the same as in normal volume. Flow rates are greater than 
normal at comparable lung volume  because  the increased elastic recoil 
of lungs holds the airways open. 
Interpretation 
Interpretation of spirometry results should begin with an assessment of test 
quality. Failure to meet performance standards can result in unreliable test 
results. The American Thoracic Society (ATS) defines acceptable spirometry 
as an expiratory effort that shows (1) minimal hesitation at the start of the 
forced expiration (extrapolated volume (EV) £5% of the FVC or 0.15 L, 
whichever is larger), (2) no cough in the first second of forced exhalation, and 
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(3) meets 1 of 3 criteria that define a valid end-of-test: (a) smooth curvilinear 
rise of the volume-time tracing to a plateau of at least 1-second duration; (b) if 
a test fails to exhibit an expiratory plateau, a forced expiratory time (FET) of 
15 seconds; or (c) when the patient cannot or should not continue forced 
exhalation for valid medical reasons.
[25]
 
      In patients that have significant loss of lung elastic recoil (pulmonary 
emphysema), spirometry may show "negative effort dependence of forced 
expiratory flow." In other words, the effort that has the highest peak expiratory 
effort may produce a lower FEV1 because of dynamic compression of the 
larger airways. In this circumstance, the effort with the highest FEV1produced 
by a submaximal effort should not be reported. Although not yet a standard, it 
appears that selecting only efforts that have a time to peak flow (TPEF) less than 
or equal to 0.12 seconds helps eliminate this effect.
[46,47]
 
      Additionally, the 2 largest values for FVC and the 2 largest values for 
FEV1 in the same testing session should vary by no more than 0.15 L (0.1 L if 
the largest value is < 1 L). A recent study has shown start-of-test problems 
(affecting FEV1 measurements) to be relatively uncommon (2% prevalence in 
one series) and end-of-test problems (affecting FVC quality) being very 
common (61-84% prevalence). Allowing the patient to relax and push gently 
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after 3-4 seconds of forced exhalation has been shown to greatly enhance the 
ability of patients with airflow obstruction to satisfy end-of-test criteria.
 [51] 
  
      Inspection of the volume-time tracing aids in identification of early 
termination of expiration by evaluating the presence of an expiratory plateau. 
In the absence of an expiratory plateau, a 12- to 15-second expiratory time 
ensures the quality of the FVC. Inspection of the start of the volume-time 
tracing can identify a hesitant start, which can result in a falsely low FEV1. 
Reproducibility of the FVC and the FEV1 helps ensure that the results truly 
represent the patient's lung function. Attention should be focused on 3 key 
parameters: FVC, FEV1, and the FEV1 -to-FVC ratio.
[45]
 
       In the United States, normal values and lower limits of normal defined by 
Hankinson et al.
[26]
 (the National Health and Nutrition Examination Survey 
[NHANES] III predicted set) should be used. These provide specific equations 
for whites, African Americans and Mexican Americans. If the patient belongs 
to another ethnic group, the predicted values and lower limits of normal 
provided for whites by Hankinson et al should be reduced by 12% by 
multiplying the predicted value by 0.88 before comparison with the patient's 
results.
[48,49]
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     Disproportionate reduction in the FEV1 as compared to the FVC (and 
therefore the FEV1 -to-FVC ratio) is the hallmark of obstructive lung diseases. 
This physiologic category of lung diseases includes but is not limited to 
asthma, acute and chronic bronchitis, emphysema, bronchiectasis, cystic 
fibrosis, pneumonia, alpha1-antitrypsin deficiency, and bronchiolitis. The 
expiratory flow at any given expiratory volume is reduced. The mechanism 
responsible for the reduction in airflow can be bronchial spasm, airway 
inflammation, increased intraluminal secretions, and/or reduction in 
parenchymal support of the airways due to loss of lung elastic recoil.
[52]
 
       The use of a fixed lower limit of normal for the FEV1/FVC ratio as 
proposed by the Global Initiative for Obstructive Lung Disease (GOLD) lacks 
a scientific basis and results in misclassifying patients at either end of the age 
spectrum. Young patients are classified as "normal" when airflow obstruction 
is present, and older patients are classified as showing obstruction when no 
airflow obstruction is present. The use of the GOLD threshold in clinical 
practice should be discouraged.
[39]
 
       Reduction in the FVC with a normal or elevated FEV1 -to-FVC ratio 
should trigger further diagnostic workup to rule out restrictive lung disease. 
Because the FEV1 is a fraction of the FVC, it also is reduced, but the FEV1 -to-
FVC ratio is preserved at a normal or elevated level. 
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LUNG VOLUMES 
Fig 5 :Lung volumes 
 
FVC 
Forced vital capacity, volume change between a full inspiration to total lung 
capacity and a maximal expiration to residual volume. 
FEV1 
Forced expiratory volume at 1 second, volume of air that can be expired in 1 
second after a maximal inspiration. 
FEV1/FVC 
Ratio between FEV1 and FVC. 
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FEV1/FEV6 
Ratio between FEV1 and FEV6. This is a test that is used in the primary care 
or physicians office setting because it is easier to perform and obtain from the 
patient. 
FEF 25-75% 
The average expired flow over the middle half of the FVC and is regarded as a 
more sensitive measure of small airways narrowing than the FEV1. 
PEF 
Peak expiratory flow, maximum flow generated during expiration performed 
with maximal force and started after a full inspiration. 
FRC 
Functional Residual CapacitJy, volume of gas contained in the lung after a 
normal expiration. 
IVC 
Inspiratory Vital Capacity, the volume change between a maximal expiration to 
residual volume and a full inspiration to total lung capacity. 
MVV 
Maximal Voluntary Ventilation, a measure of the maximum amount of air that 
can be inhaled and exhaled in one minute, measured in liters/minute. 
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RV 
Residual Volume, volume that remains in the lungs after a maximal expiration, 
cannot be measured by spirometry. 
TLC 
Total Lung Capacity, the volume of gas contained in the lung after a full 
inhalation, cannot be performed by spirometry because it includes the residual 
volume. 
VC (Vital Capacity) 
The volume change between a full inspiration and a maximal expiration. 
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REVIEW OF LITERATURE 
                 1) Hiroshi Mori et al examined the possible association between the 
vascular complications of diabetes and changes in pulmonary function, they 
performed pulmonary function tests including assessment of the diffusing 
capacity (%DLco) in 80 patients with non-insulin dependent diabetes mellitus 
(45 males and 35 females) without overt lung or heart disease was performed. 
The mean age of the subjects was 57.9 years and the mean duration of diabetes 
was 10.8 years. The %DLco decresed significantly as the duration of diabetes 
increased (r=-0.38, p<0.01), and the same relationship was also observed in 
non-smoking individuals (n=37) ,The reduction in %DLco was greater in 
patients with diabetic microangiopathy (especially nephropathy) and in those 
treated with insulin. Other spirometric functions showed no relationship to the 
duration of DM, the degree of microangiopathy or the type of treatment. These 
results suggest that diabetic microangiopathy play on important role in the 
decrease of %DLco.
 [36]
 
                          In this study, %DLco was found to correlate negatively with 
duration of diabetes. Asanuma et al, and Sandler at al have reported that as the 
duration of diabetes increase, the pulmonary diffusion capacity is decreased. 
Uchida et al in a study of ventilation-perfusion scintigrams in diabetics, 
observed a decreased pulmonary diffusing capacity in patients with perfusion 
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defect. As these patients had a longer duration of diabetes and a higher 
incidence of retinopathy, pulmonary microangiopathy was suggested.
 [36]
 
                    2) Walter.E.Robert, Alexa Beiser, Rachel J, Givelber,George T, 
O’Connor, et al. studied “Association between glycemic state and lung 
function”.  
          This study was conducted to analyze the relationship of diabetes 
and of fasting blood sugar to level of Pulmonary function test by Spirometric 
assessment in 87 members of Framingham and pulmonary function FEV1, 
FVC & FEV1/FVC ratio was detorating Collins survey 11 Spirometer and the 
predicted pulmonary function test was determined by the coefficients of 
regression of pulmonary function test on age, sex and body habitus.  
Results :  
       The diabetes and a higher levels of FBS were associated with lower 
pulmonary function-The FVC was lower by 109 ml, FEV1 was lower by 27 ml 
and FEV1/FVC% was higher by 1.5% in the diabetics compared to non 
diabetics.
[27]
 
 
3) Lange P. et al Studied- the possible association between diabetes 
mellitus, plasma glucose, forced vital capacity and forced 
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expiratory volume in 1 second in 11,763 subjects of 20yrs or older 
284 of the participants were with diabetes mellitus.  
Results:  
There was a slight impairment of lung function it was more prominent 
in subjects treated with insulin than those taking oral hypoglycemic 
agents and/or diet, FVC was reduced by 334ml and FEV1 239ml in 
subjects treated with insulin and FVC was reduced by 184ml and 
FEV1 117ml in subjects treated with oral hypoglycemic agents and/or 
diet compared to controls. 
[28]
 
           
                4)  SCHNAPF et al found that there was reduction of lung volumes 
in IDDM patients when the patients also had decreased joint mobility. 
Consequently, it has been suggested that non-enzymatic glycosylation of 
connective tissue, especially the collagen, might be responsible for both lung 
and jont abnormalities. Their findings of an association between raised values 
of plasma glucose and lung function impairment are in accordance with this 
hypothesis.
 [38]
 
       The prevalence of self reported DM in their study sample was 2.5%, which 
is slightly higher than the estimated prevalence of DM of 1-1.5% in the Danish 
population. This is due to age stratified sampling used in the present study 
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resulting in the bulk of the participants in the age group being between 40-70 
years, in whom the prevalence of NIDDM can be as high as 4.5%. However 
the age distribution and the treatment regimes strongly suggests that the great 
majority of the diabetic subjects investigated had NIDDM. This means that 
some of the subjects in the DM1 group, especially the ones older than 60 years 
of age were suffering from NIDDM in spite of treatment with insulin. 
          Due to small number of diabetic subjects in many of the subgroups, the 
study does not allow detailed analysis of the impact of DM on ventilator 
function in the different age group. Even so, the slight lung function 
impairment in the diabetic subjects was present in all age groups and there was 
no significant interaction between age and DM in the regression analysis. 
           Many confounding factors might lead to reduction of both FEV1 and 
FVC in diabetic subjects. Two of them are obesity and cardiac failure. As 
many subjects with NIDDM are obese, the reduction of FEV1 and FVC in 
NIDDM might therefore be the result of being overweight rather than the result 
of NIDDM. However since they included BMI in the regression model, obesity 
was unlikely to be an explanation for observed lung function impairment. In 
addition, the most pronounced lung function impairment was in the DM1 
group. Although none of the diabetic subjects had manifest heart failure during 
the examination, it was not possible to exclude that a mild pulmonary 
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congestion was present in some of the diabetic subjects, as ischemic heart 
disease is more prevalent in subjects with DM than in normals.
 [38] 
       5) Davis A Wendy, Matthew Knuiman, Peter Kendell, Valerie Grange, 
Timothy M.E.Davis et al Studied- Glycemic exposure is associated with 
reduced pulmonary function test in Type 2 diabetes. 
     In this study 495 patients with Type-2 DM who had no history of 
pulmonary disease was studied between 1993 and 1994 by community –based 
cohort study and 125 patient was restudied 7 years later for FVC, FEV1, VC & 
PEF corrected for BTPS and were expressed as absolute terms or as percentage 
predicted for age, sex and height.  
Results:  
There was a decrease in mean percentage-predicted values of each 
Spirometric measure to 10% in the whole cohort study at baseline and absolute 
measures continued to decline at an annual rate of 68ml, 71ml and 84ml/year 
and 17 l/min for FVC, FEV1, VC and PEF 
[29] 
respectively in the study group 
    6) Malcolm sander et al Studied-Is lung a ‘target organ’ in diabetes mellitus.  
There is a histopathological evidence of lung involvement in subjects 
with diabetes mellitus by thickened alveolar epithelial and pulmonary capillary 
basal laminae suggestive of pulmonary microangiopathy. Abnormal pulmonary 
function has been detected in diabetic patients such as reduced lung volumes, 
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reduced pulmonary elastic recoil in diabetes, impaired diffusion due to a 
reduced pulmonary capillary blood volume and nonenzymatic glycosylation-
induced alteration in the lung connective tissue is the most likely pathogenesis 
mechanism underlying the mechanical pulmonary dysfunction
[21] 
 in diabetic 
subjects.  
        7) Spomenka Ljubic et al study  showed a reduction of diffusion capacity 
for carbon monoxide in DM patients. Diabetes can cause the development of 
pulmonary complications due to collagen and elastin changes, as well as 
microangiopathy. This study demonstrates the relationship between pulmonary 
complications and other chronic complications of diabetes. 27 patients with 
diabetes, aged 21 to 62 years, who had the disease from 3-32 years, were 
included in this study. The protein excretion rate(PER) and the diffusion 
capacity of the lung for carbon monoxide (DLco) were included as parameters 
of the severity of complications. PER was determined by Biuret method. DLco 
was measured by single breath method and was corrected by the measurement 
of alveolar volume (V/A).
 [23] 
  The values of DLco as corrected by V/A 
(DLco/VA) were included in the statistical evaluation of the results. The 
variations of age, duration of DM, and complication parameters were included 
in a multiple regression model with forward, stepwise selection to asses their 
value in predicting DLco/VA. The variables were found to be significant 
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predictors of DLco/VA (R2=0.46, R2=0.32, p<0.022). However, proteinuria 
was the only significant independent predictor of DLco / VA. This finding 
indicates that both renal and pulmonary complications of diabetes share a 
similar microangiopathic background. 
       8)  Davis Timothy M. E, Matthew Knuiman, Peter Kendell, Hien Vu, 
Wendy A. Davis et al Studied – Reduced pulmonary function is associated in 
Type-2-Diabetes mellitus.  
          The study was conducted on 421 subjects. Detailed demographic and 
diabetic specific-data were collected, spirometry was performed and FVC, 
FEV1, VC and PEF were measured and were expressed as percentage of 
prediction values for age, sex and height the means of all Spirometric measures 
were reduced by 9.5%. HbA1c was not associated with any measure of lung 
function but the diabetes duration was significantly associated with FEV1% 
prediction and PEF % prediction had borderline associations with FVC% 
prediction and VC% prediction.
[30]  
Pulmonary function is reduced in type 2 
DM and diabetes duration has more influence on pulmonary function than the 
glycemic control. 
     9)  Sreeja C.K, Elzabeth Samuel, C.Kesava chandran, Shankar Shashidaran. 
et al Studied- Pulmonary function in patients with Diabetes mellitus.
[40]
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           Lung function tests were carried out in20 Type2Diabetes mellitus and 
20 Type1 Diabetes mellitus and 40 subjects as controls. There was a significant 
reduction in FEV1/FVC% in both diabetes mellitus groups compared with 
controls. The decrease in FEV1/FVC% in both the groups may be related to the 
poor mechanical properties of lung. Viz lung compliance and elastic recoil of 
lungs, TLC was lower in diabetes mellitus group because of alteration in 
collagen and elastin by loss of elastic recoil and low lung volumes and 
abnormal pressure volume relationship may be due to the respiratory muscle 
weakness. 
[31,40]
 
        10) SK Rajan et al study of spirometric evaluation of type 1 DM, was a 
cross sectional study of 30 patients (group1) who are on insulin therapy. Group 
2 consisted of age matched, non-smoking healthy volunteers who acted as 
controls. Spirometric revealed normal findings in 10 patients (33%), and 
abnormal findings in 20 patients (67%). Among these 20 patients with 
abnormal findings obstructive pattern in 8 patients, restrictive pattern was 
present in 9 patients and mixed pattern was observed in 7 patients. This study 
showed that the lung has to be considered as one of the target organs in type 1 
DM. In view of  the possibility pneumopathy in asymptomatic type1DM, all 
persons with long –standing type1DM should  undergo regular assessment of 
pulmonary function.
 [37]
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       DM is associated with widespread hormonal, metabolic and micro vascular 
abnormality, as well as with disturbances of the function of many organ 
systems. The kidneys. Eyes, cardio vascular system and respiratory system can 
be damaged. The aim of the study was to investigate lung function in DM and 
renal complications. The development of these complications could be 
explained by the biochemical alteration of connective tissue constituents, 
particularly collagen and elastin, as well as micro angiopathy due to a non-
enzymatic glycosylation of proteins induced by chronic hyperglycemia. 
          Collagen is an abundant structural protein found in the previously 
mentioned organic systems, so the disturbance of the function of those systems 
can be expected. The kidneys, eyes and lungs of  patients with diabetes are 
affected consequently, and the patient develops obstructive and restrictive 
disorders. As a result of alveolar capillary membrane thickenings due to 
collagen and elastin alterations and microangiopathy, the capacity for the 
diffusion of carbon monoxide is reduced. 
        An altered rate urinary protein excretion due to glomerular capillary injury 
also can be found. The aim of this study was to assess the presence of 
pulmonary complications. The values the proteins excretion rate and the 
diffusion capacity for carbon monoxide (DLco) corrected by alveolar volume 
were compared for this purpose. Also, they investigated the development of 
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retinopathy and its connection with the previously mentioned renal and 
pulmonary complications, because it is believed that they share a similar 
etiopathogenic mechanism.   
      11) Benbassat Carlos A, Ervin Stern, Mordechai Kramer, Joseph Lebzelter, 
Ilana  Blum, Gershon Fink et al Studied -pulmonary function in patients with 
Diabetes mellitus.  
Pulmonary complications of diabetes mellitus have been poorly 
characterized. Some have reported normal pulmonary function test others have 
found abnormal lung volumes, pulmonary mechanics and diffusing capacity.  
The study was conducted in patients with DM using a combined 
cardiopulmonary exercise test in 27 patients with DM aged 48 ± 13 years. The 
FVC, FEV1 and FEF, MEF were within the predicted values, but the residual 
volumes and TLC ratio was slightly elevated. Comparison by diabetes type 
showed no significant differences in FEV1 and FEF, MEF, residual volumes 
and TLC ratio was significantly elevated in Type-1 DM compared with Type2-
Diabetes mellitus. There was no correlation between the pulmonary function 
test and duration of disease, presence of microangiopathy or glycemic 
control.
[32] 
         12) Dr.Mohankumar and Dr.S.Arulmozhi et al Studied –Pulmonary 
complications in elderly diabetics.In diabetes mellitus the total lung capacity, 
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lung volume and lung compliance are reduced, the central and peripheral 
airflows are reduced, and acceleration of aging process in pulmonary 
connective tissue are seen. There is interference with connective tissue cross-
links and the presence of increased non-enzymatic glycosylation, and 
modification of alveolar surfactant action. The diffusing capacity for carbon 
monoxide is reduced because of pulmonary microangiopathy in diabetes 
mellitus. 
[44,7] 
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AIM OF THE STUDY 
            
 To study the ventilatory function of individuals with type 2 
diabetes mellitus by performing spirometry. 
 To record the pulmonary function test in Type-2 diabetes mellitus 
and control group.  
 To evaluate the impact of Type-2 DM on pulmonary functions by 
comparing with control groups.  
 To correlate the spirometric values and variables(duration,FBS, 
PPBS,HbA1c) of  diabetes. 
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MATERIALS AND METHODS 
        A case-control study, descriptive, prospective study of the lung function 
of diabetics compared with age and sex-matched non-diabetic controls. 
Sample size:  
The sample used in this study consisted of 100 subjects – 50 Diabetics, 50 
Healthy Non-Diabetics. 
Sampling procedure:  
50 Diabetic individuals were recruited from those attending outpatient 
departments of Government Rajaji Hospital, Madurai. 50 Healthy Non-
Diabetic individuals from the general population were taken as controls. 
Ethical clearance:  
Ethical clearance was obtained from Government Rajaji Hospital  ethical 
committee for human research to conduct the study. 
Inclusion criteria:  
 Type 2 diabetes mellitus of more than 5 years duration  
 able to give informed consent. 
Exclusion criteria: 
 Smokers 
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 Present or past history of respiratory illness that might affect lung 
function such as asthms, COPD, tuberculosis, bronchiectasis, interstitial 
lung disease. 
 History of occupational exposure to any substance that could affect lung 
function. 
 Individuals with current or recent upper respiratory or lower respiratory 
infection, that could predispose to heightened airway reactivity. 
 Individuals with unacceptable spirometric technique. An unacceptable 
spirometry was that in which FEV1 or FVC could not be correctly 
measured due to 
 Cough 
 Obstruction of teeth or toungue 
 Sub-maximal effort 
 Air escape 
 Effort sustained for less than 6 seconds duration 
 Lack of understanding of the procedure 
 Recent thoracic and abdominal surgery 
Materials  
         Micro medical spirometer, weighing scale, stadiometer, Microsoft excel. 
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Methodology  
Diabetics and controls were selected as per the criteria laid down. Their written 
consent was taken. The screening of diabetic subjects and control group was 
done for exclusion criteria. The history was elicited. Age, height, weight, BMI 
were recorded. Each subject was instructed to visit cardio respiratory 
laboratory with 6 hrs of fasting on a specific date, the blood samples [3ml 
volume] was drawn for estimation of FBS and glycated hemoglobin. 
       Performance of PFT by a patient 
 
The performance of the pulmonary function test was demonstrated. The 
subjects and controls were made to undergo pulmonary function test using the  
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MICRO MEDICAL computerized Spirometer, for three times at every 15 
minutes interval. The FVC, FEV1, PEF, FEV1/FVC% and FEF25-75% were 
recorded. And the best of the three was taken into account. The subject was 
asked to take breakfast and blood sample was drawn 2 hrs later for PPBS 
estimation. 
         The anthropometric, respiratory, blood glucose parameters and glycated 
Hb levels were recorded in their respective proforma. 
Statistical Tools   
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square  test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
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OBSERVATION AND RESULTS 
A total number of 100 subjects were suitable for analysis. There were 50 
diabetics (CASES)  and 50 non-diabetic group (CONTROL) 
A : PROFILE OF CASES STUDIED 
                                   
                                             Table 1 : Age distribution 
Age group 
Cases group 
Control 
group 
No % No % 
Upto 40 years 2 4 6 12 
41-50 years 35 70 28 56 
51-60 years 13 26 16 32 
Total 50 100 50 100 
Range 39-58 years 36-57 years 
Mean 46.6 years 47.48 years 
SD 5.01 years 5.21 years 
‘p’ 
0.6123 
Not significant 
 
The Diabetes group had an age of 46.6 +5.01 years and the Control group 47.48 
+5.21 years. There was no statistically significant difference. 
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                                            Fig 6 : Age distribution 
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                                          Table 2 : Sex distribution 
 
Sex 
DM Cases 
group 
Control 
group 
No % No % 
Male 27 54 28 56 
Female 23 46 22 44 
Total 50 100 40 100 
‘p’ 
0.9193 
Not significant 
 
Sex distribution of the study group and control group did not have any 
significant difference ( p = 0.9193). 
                                        Fig 7 : Sex distribution 
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Table 3 : Physiological variables  
Variable 
DM Cases 
group 
Control group 
‘p’ 
Mean SD Mean SD 
Height ( in cms) 164.92 6.04 162.34 7.85 
0.6642 
Not significant 
Weight ( in kgs) 66.30 8.70 67.14 10.51 
0.646 
Not significant 
BMI 24.30 2.2 25.69 4.9 
0.762 
Not significant 
 
Height ,weight and BMI of the control and Diabetic cases studied did not have 
any significant difference ( p > 0.05). 
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Fig 8 : Physiological variables  
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                                         Table 4 : Blood Sugar levels 
Blood Sugar 
DM Cases 
group 
Control group 
‘p’ 
Mean SD Mean SD 
Fasting 193.12 53.70 88.00 10.12 
0.0001 
Significant 
Post prandial 267.16 63.28 125.74 11.31 
0.0001 
Significant 
 
The P value for the basic characters FBS and PPBS is <0.0001 is significant. 
 
                               Table 5 : Duration of Diabetic cases 
Duration in years No.of cases % of cases 
5-6 14 28% 
7-8 17 34% 
9-10 14 28% 
>10 5 10% 
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          Fig 9 : Mean blood sugar values between cases and controls 
 
                              Fig 10 : Duration of Diabetic cases 
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The pulmonary function test was conducted on 50 Type-2 diabetics with a 
history of diabetes for more than 5 yrs duration and 50 healthy individuals. An 
attempt was made to evaluate the effect of Type-2 DM on pulmonary functions. 
The effect of extent of diabetes status as reflected by FBS, PPBS, HB1Ac and 
duration on pulmonary function was also evaluated. The pulmonary function 
tests recorded were FVC, FEV1, FEV1/FVC%, PEF and FEF25%-75%.  
The basic character’s Age, sex, height, weight, BMI, FBS and PPBS of 
cases and controls, are shown in the table 3&4. The P value for the basic 
characters FBS and PPBS is <0.05 which is significant, however the basic 
character’s age, sex, ht, wt, BMI and P value is >0.05 which is not significant. 
B : Effect of Type-2 diabetes mellitus on pulmonary function test 
                         Table 6: Observed Spirometric results 
Pulmonary 
function test  
 
DM Cases group 
(n=50) 
Control group 
(n=50) 
 
P 
Value 
Significance 
Mean SD Mean SD 
FVC 2.67 0.48 3.25 0.24 0.0001 Significant 
FEV1  1.68 0.37 2.32 0.38 0.0001 Significant 
FEV1/FVC 
Ratio  62.75 6.9 72.02 11.01 0.0001 Significant 
PEF  400.52 118.92 448.94 105.40 0.0336 Significant 
FEF 25-75  2.34 0.55 2.69 0.53 0.0022 Significant 
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Table 7 : % Predicted values  of   PFT 
Pulmonary 
function test 
 
DM Cases group 
(n=50) 
Control group 
(n=50) 
 
P 
Value 
Significance 
Mean SD Mean SD 
FVC 68.26 16.7 84.72 13.4 0.0001 Significant 
FEV1  53.88 15.03 76.46 13.84 0.0001 Significant 
FEV1/FVC 
Ratio  
78.95 8.2 90.7 13.21 0.0001 Significant 
PEF  79.23 17.69 86.46 10.78 0.0155 Significant 
FEF 25-75  77.23 19.73 91.62 20.13 0.005 Significant 
 
Spirometric values were consistently lower in Diabetic case groups than control 
groups. However, the differences were statistically highly significant for 
FVC,FEV1 &FEV1/FVC ratio (p=0.0001) and moderately significant for PEF 
& FEF 25-75%.(p=0.0155,p=0.005) 
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Fig11:Comparison of spiromtric values among Diabetics and Non Diabetics 
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C: Relationship between spirometric values and other  variables in 
Diabetics 
PFT and DURATION 
Table 8 : Duration and Observed Spirometric results 
 
 
Observed spirometric values were inversely related to the duration of diabetes. 
as the duration increases the spirometric values were consistenly decreased, 
which is highly significant for all parameters. (p<0.005) 
 
 
 
 
 
 
Pulmonary 
function 
test 
 
Duration of DM group in years (Mean ± SD) 
 
 
 
P 
Value 
Significance 
5-6 (n=14) 7-8 (n=17) 9-10 (n=14) >10 (n=5) 
FVC 2.85±0.63 2.68±0.38 2.28±0.34 2.02±0.42 0.001 Significant 
FEV1 1.94±0.44 1.76±0.39 1.57±0.22 1.28±0.12 0.003 Significant 
FEV1/FVC 78.86±5.75 73.83±4.92 74.69±5.36 71.86±4.71 0.003 Significant 
PEF 484.99±121.91 417.41±93.8 326.36±84.9 314.4±107.86 0.001 Significant 
FEF25-75 2.60±0.53 2.50±0.6 2.30±0.44 1.84±0.54 0.004 Significant 
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Table 9 : Duration and% Predicted values  of   PFT 
 
 
There was a negative correlation between the spirometric parameters and the 
duration of diabetes, which is statistically significant for all parameters except 
FEF 25-75%. 
 
 
 
 
 
 
 
Pulmonary 
function 
test 
 
Duration of DM group in years (Mean ± SD) 
 
 
 
P 
Value 
Significance 
5-6 (n=14) 7-8 (n=17) 9-10 (n=14) >10 (n=5) 
FVC 68.66±18.19 68.14±17.68 65.09±11.26 52.09±5.75 0.019 Significant 
FEV1 57.78±15.15 55.44±16.5 52.74±11.25 56.78±16.06 0.05 Significant 
FEV1/FVC 78.86±5.75 75.26±5.19 73.84±4.92 71.86±4.71 0.032 Significant 
PEF 88.45±13.48 77.64±17.62 69.7±16.36 63.94±9.08 0.006 Significant 
FEF25-75 71.66±21.44 81.15±19.68 73.84±4.92 71.86±4.71 0.059 
Not 
Significant 
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            Fig 12 : Duration and% Predicted values  of   PFT 
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 Fig 13  : Comparison of %Predicted FEV1/FVC with duration of Diabetics 
 
 
 
 
 
 
 
 
 
 
 
 
50
60
70
80
90
100
110
4 6 8 10 12
PPBS 
FEV1/FVC % 
FEV1/FVC %
58 
 
 
PFT AND FASTING BLOOD SUGAR  LEVEL 
             Table 10 : FBS Level and Observed Spirometric results 
Pulmonary 
function test 
 
FBS (mg/dl) in DM group (Mean ± SD)  
 
P 
Value 
Significance 
<130 (n=8) 
131-200 
(n=23) 
201-300 
(n=19) 
FVC  3.24±0.84 2.64±0.66 2.22±0.58 0.011 Significant 
FEV1  2.53±1.29 1.81±0.44 1.68±0.29 0.012 Significant 
FEV1/FVC  84.85±1.76 76.11±5.75 73.8±4.59 0.001 Significant 
PEF  467.25±140.49 415.26±120.2 355±96.11 0.046 Significant 
FEF25-75  2.94±1.42 2.43±0.62 2.33±0.51 0.25 
Not 
Significant 
 
             
Observed spirometric values were inversely related to the Fasting blood sugar 
level of diabetes. as the blood sugar level  increases the spirometric values were 
consistenly decreased, which is statistically significant. 
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Table 11 : FBS level and% Predicted values  of   PFT 
Pulmonary 
function test 
 
FBS (mg/dl) in DM group (Mean ± SD)  
 
P 
Value 
Significance 
<130 (n=8) 
131-200 
(n=23) 
201-300 
(n=19) 
FVC  70.2±4.28 69±18.27 63.74±12.86 0.005 Significant 
FEV1  57.29±2.7 56.11±15.22 55.81±13.56 0.009  Significant 
FEV1/FVC  78.9±1.7 76.11±5.74 74.85±6.04 0.04 Significant 
PEF  76.27±21.8 80.73±18.28 72.35±14.85 0.279 
Not 
Significant 
FEF25-75  61.7±19.9 76.53±19.79 82.54±18.91 0.148 
Not 
Significant 
 
 
 
Poor glycemic control were reflected in Pulmonary function test as fasting  
blood sugar level increases the spirometric values were decreased with 
significant p value for FVC,FEV1 and FEV1/FVC ratio.  
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                  Fig 14 : FBS level and% Predicted values  of   PFT 
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      Fig 15 : Comparison of FEV1/FVC ratio with FBS among Diabetics 
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PFT AND POSTPRANDIAL BLOOD SUGAR  LEVEL 
              Table 12 : PPBS Level and Observed Spirometric results 
Pulmonary 
function test 
 
PPBS (mg/dl) in DM group (Mean ± SD)  
P 
Value 
Significance 
<200 (n=10) 
201-300 
(n=26) 
>300 (n=14) 
FVC  2.7±0.83 2.55±0.57 2.36±0.41 0.003 Significant 
FEV1  2.23±0.59 1.77±0.39 1.57±0.36 0.002 Significant 
FEV1/FVC  80.1±5.63 76.11±5.03 74.04±4.87 0.002 Significant 
PEF  444.69±140.03 362.1±113.72 317.36±98.8 0.036 Significant 
FEF25-75  2.63±0.55 2.21±0.43 2.11±0.34 0.014 Significant 
 
 
High post prandial blood sugar levels were also associated with  Low 
spirometric values, which is highly significant for all parameters of spirometry 
with the p value of <0.05. 
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          Table 13 : PPBS level and% Predicted values  of   PFT 
Pulmonary 
function test 
 
PPBS (mg/dl) in DM group (Mean ± SD)  
 
P 
Value 
Significance 
<200 (n=10) 
201-300 
(n=26) 
>300 (n=14) 
FVC  67.77±14.48 65.67±15.7 63.65±18.97 0.0180 Significant 
FEV1  60.63±12.66 54.97±14.04 49.55±15.70 0.0178 Significant 
FEV1/FVC  75.10±3.88 73.73±5.6 71.47±6.91 0.028 Significant 
PEF  73.19±21.59 80.65±16.74 73.61±15.24 0.349 
Not 
Significant 
FEF25-75  67.39±13.85 74.45±17.9 90.84±21.16 0.006 Significant 
 
 
The % predicted values of spirometry and postprandial blood sugar levels were 
statistically significant for FVC,FEV1,FEV1/FVC with p<0.05, which indicate 
poor glycemic control were reflected in pulmonary functions with the decline of 
spirometric parameters. 
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                Fig 16 : PPBS level and% Predicted values  of   PFT 
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Fig 17 : Comparison of %Predicted FEV1/FVC with PPBS among Diabetics 
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PFT AND HbA1c LEVEL 
 
Table 14 : HbA1c Level and Observed Spirometric results 
Pulmonary 
function test 
 
HbA1c (mg/dl) in DM group (Mean ± SD)  
P 
Value 
Significance 
5-7(n=18) 7.1-9(n=24) >9(n=8) 
FVC  2.75±0.60 2.49±0.48 1.81±0.66 0.001 Significant 
FEV1  1.98±0.47 1.76±0.33 1.53±0.20 0.019 Significant 
FEV1/FVC  64.35±5.28 61.08±5.54 58.67±3.4 0.028 Significant 
PEF  458.83±140.81 371.54±92.43 356.25±94.28 0.029 Significant 
FEF25-75  2.57±0.54 2.37±0.53 2.14±0.59 0.59 
Not 
Significant 
 
 
Observed spirometric results were negatively correlated with HbA1c levels with 
significant p (<0.05) value for FVC, FEV1, FEV1/FVC,PEF. Which indicates 
poor glycemic control was associated with pulmonary functions. 
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Table 15 : HbA1c level and% Predicted values  of   PFT 
Pulmonary 
function test 
 
HbA1c  (mg/dl) in DM group (Mean ± SD)  
P 
Value 
Significance 
5-7(n=18) 7.1-9(n=24) >9(n=8) 
FVC  66.16±16.85 59±16.21 59.81±13.9 0.034 Significant 
FEV1  58.67±15.15 53.29±15.07 51.06±10.49 0.039 Significant 
FEV1/FVC  76.86±5.76 75.08±5.96 73.9±3.85 0.040 Significant 
PEF  84.83±19.32 74.21±14.23 68.91±17.15 0.046 Significant 
FEF25-75  75.93±20.98 79.92±19.68 75.45±19.84 0.78 
Not 
Significant 
 
 
Poor glycemic control were also reflected in Pulmonary function test as HbA1c 
level increases the spirometric values were decreased with significant p value 
for FVC,FEV1 and FEV1/FVC ratio.  
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                Fig 18 : HbA1c level and% Predicted values  of   PFT 
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 Fig 19 : Comparison of %Predicted FEV1/FVC with HbA1c among Diabetics 
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DISCUSSION 
This study was undertaken to assess the pulmonary function of type 2 
diabetes mellitus patients, and to compare it with those of non-diabetic healthy 
subjects. Few studies have focused on the relationship between pulmonary 
function and diabetes. 
The different groups i.e., cases and controls were comparable in terms of 
age, height, weight and BMI. These being the major determinants of the 
spirometric values, the main determinant of spirometry were likely to be the 
presence or absence of diabetes. 
The groups were also homogeneous in respect of  having no known 
respiratory disease, and all being non-smokers. In the study of  Hirishi Mori et 
al, smokers were included in the analysis, and this was therefore an additional 
confounding variable. 
The effect of diabetes in pulmonary function tests were observed and the 
Spirometric values were consistently lower in Diabetic case groups than control 
groups.  
 
71 
 
The present study is in agreement with Walter.E.Robert et al who studied 
the relationship between diabetes mellitus and pulmonary function and showed a 
decrease in FVC by 109ml and FEV1 by 27ml   in diabetes mellitus.
[27] 
Davis 
M.E. Timothy studied the pulmonary function and its association with Type-2 
diabetes mellitus and showed an average decrease of 9.5% in FVC and FEV1 of 
diabetics. 
[29]
His study was also showed a 1.5% increase in the FEV1/FVC %
[27] 
with a P value <0.05% which is statically significant. Suggesting a restrictive 
pattern of ventilatory impairment.  
In SK Rajan’s study, spirometric readings of study group patients 
revealed that 60% showed an obstructive pattern, 30% showed a restrictive 
pattern, and 10%  showed a  mixed pattern.
 [37]
 
In our study, we found a predominantly restrictive pattern with a FVC & FEV1 
were  <80% of the predicted value and FEV1/FVC ratio were >70% of the 
predicted. 
Duration and other parameters were compared with all values of spirometry, 
during which the following results were observed: 
1) There was tendency for all parameters to fall with longer duration of 
diabetes. However, a multiple regression analysis showed that this was 
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not significant. Clearly, those with a longer duration of diabetes also were 
older, and the effect of decling in lung function with age was a greater 
contributing factor. 
2) Poor diabetic control was associated with poorer lung function. There was 
a association between greater declines in FVC,FEV1 &FEV1/FVC and 
higher values of FBS and PPBS. 
3) A similar inverse association was noted between higher HbA1c levels and 
lower spirometric values. 
In the study of Marco Guzzi et al, absolute values and percentage of 
predicted normal values of FEV1, MVV, vital capacity and total lung 
capacity were reduced in NDDIM patient group. DLco showed a step wise 
highly significant reduction from normal to hyperglycaemic.
 [35]
 
In Hiroshi Mori study people says %DLco was negatively correlated with 
duration of diabetics, but other PFTs like %VC, FEV1 or PaO2 did not show 
such a negative correlation.
 [36]
 
        In P Lange’s study, the diabetic subjects had slightly smaller height 
adjusted FEV1 & FVC compare values of non-diabetic subjects, their regression 
analysis also, showed association between raised values of plasma glucose and 
reduction of the lung function was highly significant.
 [28] 
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CONCLUSION 
The present study was undertaken to resolve conflict between two schools of 
thought, one expounding impact of Type-2 diabetes mellitus on respiratory 
system and another non-impact. Pulmonary functions in Type-2 diabetes 
mellitus and controls were statistically compared to resolve this. The intra 
diabetic subgroups- FBS wise, PPBS wise, duration wise and HbA1c were 
correlated to pulmonary functions to find out the impact of  Type-2 diabetes 
mellitus on respiratory system. This study confirms the following features.  
1) The pulmonary functions FVC, FEV1, PEF and FEF25%-75% are 
decreased in Type-2 diabetes mellitus compared to controls. FEV1/FVC% 
increased in Type-2 diabetes mellitus, which is indicative of restrictive 
disorder of the lung.  
2) There were negative correlation between FBS levels and pulmonary 
functions FVC, FEV1 and FEV1/FVC. Linear relationship exists between 
increasing FBS and FEV1/FVC%, which is indicative of restrictive 
disorder of the lung.  
 
3) Poor glycemic control were reflected in pulmonary functions with the 
decline of spirometric parameters associated with high PPBS levels. 
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Linear relationship exists between increasing PPBS and FEV1/FVC%, 
which is indicative of restrictive disorder of the lung.  
4) There were negative correlation between duration of diabetes mellitus and 
pulmonary functions FVC, FEV1, PEF and FEF25%-75%. Linear 
relationship exists between increasing duration and FEV1/FVC%, which 
is indicative of restrictive disorder of the lung.  
5)  Poor glycemic control were also reflected in Pulmonary function test as    
    HbA1c level increases the spirometric values FVC, FEV1, FEV1/FVC, 
were consistently decreased.   
The above mentioned effects of Type-2 diabetes mellitus on pulmonary 
functions are all due to the alterations in pulmonary connective tissue, 
thickening of basement membrane of capillary and alveolus, modification of 
surfactant, decreased recoiling tendency of lung and decreased muscle 
endurance. 
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LIMITATIONS OF THE STUDY 
♦ The study population was small 
♦ Subjects declaration of being non-smokers was accepted at face value, we 
were not able to confidently exclude previous smoking or other irritant 
fume exposure, unless declared by our  subjects. 
♦ Cardiac failure was excluded only by history and examination,and not by 
echocardiography. It is known that mild pulmonary congestion can cause 
spirometric abnormalities. 
♦ Diffusion studies were not performed on our subjects.this was one of the 
main parameters affected according to other studies on the same subjects. 
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PULMONARY FUNCTION TESTS IN TYPE-2 DIABETES MELLITUS 
NAME:  AGE:  SEX:  
Study ID NO:  Spirometry ID NO:  OPD / IP NO:  
Height (cms):  Weight (kgs):  BMI :  
Education:  Occupation:   
 
Address:-  
 
QUESTIONNARIE  
 
History of Diabetes Mellitus:             Yes /No  
 
Symptoms:  
 
              -Polyuria                                  Yes / No  
 
             -Polydpsia                                Yes / No  
 
             -Polyphagia                             Yes / No  
 
            -Unexplained weight loss      Yes / No  
 
Duration of Diabetes Mellitus:  
 
Was Medications taken regulary:      Yes / No 
Drug  Dose  Duration taken  
   
   
   
   
 
 
 
 
 
PROFORMA
 Complications Of Diabetes mellitus: Present /Absent  
(if present) –  
 
History of smoking/Hypertension/ tabacoo chewing habitt:      Yes / No  
 
History of alcohol consumption:                                                      Yes / No  
 
History of chronic respiratory disease:                                           Yes / No  
 
History of unstable angina pectoris / M.I / C.H.F:                        Yes / No  
 
Hospitalised for last 6 mts for respiratory illness:                       Yes / No  
 
Clinical Examination:  
 
General physical examination: 
 
Temp: 
0
F  
 
Pulse: /min  Respiratory 
rate:/min  
BP: mm of 
Hg  
R.S-  
 
C.V.S-  
 
P / A-  
 
C.N.S-  
 
INVESTIGATIONS:  
 
FBS   :                mg / dl  
PPBS:                mg / dl  
HB1Ac:                % 
 
 
 
 Pulmonary 
function test  
Observed  Predicted  % Prediction  
FVC  
 
   
FEV1  
 
   
PEF  
 
   
FEF 25 % - 
75%  
 
   
FEV1/FVC%  
 
   
 
Master chart showing basic characters of control group
Sl no 
Study ID No. 
of controls age sex ht in cms wt in kgs BMI FBS mg/dl 
PPBS 
mg/dl 
51 2011051 51 Male 175 69 22.53 101 136
52 2011052 55 Male 159 85 33.62 96 132
53 2011053 52 Male 148 70 31.96 85 128
54 2011054 49 Female 154 60 25.30 76 128
55 2011055 54 Male 150 82 36.44 86 121
56 2011056 40 Male 166 56 20.32 84 135
57 2011057 41 Female 157 56 22.72 94 128
58 2011058 47 Male 175 77 25.14 80 135
59 2011059 44 Female 170 74 25.61 82 120
60 2011060 44 Male 176 67 21.63 98 126
61 2011061 39 Female 167 50 17.93 104 132
62 2011062 36 Male 154 88 37.11 78 116
63 2011063 41 Female 164 71 26.40 86 102
64 2011064 44 Female 164 66 24.54 76 121
65 2011065 56 Female 167 55 19.72 85 125
66 2011066 44 Male 171 57 19.49 94 134
67 2011067 41 Male 154 55 23.19 94 138
68 2011068 51 Female 152 68 29.43 102 118
69 2011069 50 Male 152 60 25.97 78 132
70 2011070 50 Female 160 80 31.25 95 129
71 2011071 55 Male 158 65 26.04 74 136
72 2011072 51 Male 151 73 32.02 84 135
73 2011073 50 Female 159 70 27.69 100 140
74 2011074 52 Male 154 71 29.94 85 125
75 2011075 51 Male 152 76 32.89 94 134
Master chart showing basic characters of control group
Sl no 
Study ID No. 
of controls age sex ht in cms wt in kgs BMI FBS mg/dl 
PPBS 
mg/dl 
76 2011076 47 Female 152 77 33.33 74 132
77 2011077 54 Male 160 68 26.56 82 128
78 2011078 49 Female 158 55 22.03 91 121
79 2011079 53 Male 151 57 25.00 84 106
80 2011080 38 Male 168 55 19.49 111 144
81 2011081 44 Female 168 68 24.09 82 128
82 2011082 39 Male 165 60 22.04 91 121
83 2011083 40 Female 161 80 30.86 84 106
84 2011084 47 Male 167 50 17.93 98 112
85 2011085 42 Male 167 82 29.40 112 136
86 2011086 49 Female 150 56 24.89 86 114
87 2011087 44 Male 166 56 20.32 94 138
88 2011088 46 Male 170 57 19.72 102 118
89 2011089 49 Female 167 56 20.08 76 118
90 2011090 51 Male 170 86 29.76 80 136
91 2011091 50 Female 154 70 29.52 72 132
92 2011092 51 Female 164 69 25.65 91 138
93 2011093 47 Male 164 85 31.60 82 128
94 2011094 49 Male 172 70 23.66 101 136
95 2011095 52 Female 172 60 20.28 96 132
96 2011096 57 Male 164 82 30.49 84 134
97 2011097 41 Female 169 56 19.61 76 114
98 2011098 47 Male 168 56 19.84 72 98
99 2011099 49 Female 171 70 23.94 78 116
100 2011100 50 Female 170 73 25.26 89 129
Master chart showing spirometric values of control group
Sl no 
Study ID 
No. of 
controls
Rec      
FVC 
Pred 
FVC 
% Pred 
FVC
Rec 
FEV1 
Pred 
FEV1 
% Pred 
FEV1
Rec           
PEF 
Pred       
PEF 
% Pred 
PEF
Rec 
FEF25-75
Pred 
FEF25-75 
% Pred 
FEF25-75
Rec 
FEV1/FVC
Pred 
FEV1/FVC
% Pred 
FEV1/FVC
51 2011051 3.27 4.85 67.40 2.19 3.76 58.30 576 604 95.36 2.58 3.32 77.70 67 77.5 86.40
52 2011052 3.68 3.74 98.40 2.73 2.88 94.80 484 555 87.21 2.92 2.57 113.70 74.2 76.7 96.70
53 2011053 3.19 3.2 99.80 2.12 2.5 84.80 448 540 82.96 2.6 2.37 109.70 66.5 77.3 85.90
54 2011054 3.61 3.16 114.40 2.06 2.52 81.80 332 406 81.77 2.73 2.61 104.60 57.1 80.4 71.00
55 2011055 3.22 3.25 99.00 1.52 2.52 60.30 475 537 88.45 2.9 2.3 124.40 47.2 76.9 61.40
56 2011056 3.17 4.54 69.80 2.39 3.64 65.60 606 613 98.86 2.96 3.55 83.30 75.4 79.8 94.50
57 2011057 3.3 3.42 96.50 2.76 2.79 98.80 376 425 88.47 3.62 2.97 121.80 83.6 82.1 101.90
58 2011058 3.56 4.95 71.90 2.63 3.88 67.80 543 618 87.86 2.45 3.52 69.60 73.9 78.4 94.30
59 2011059 3.32 4.01 82.80 2.73 3.22 84.80 454 436 104.13 2.83 3.16 89.60 82.2 81.5 100.90
60 2011060 3.53 5.09 69.40 2.47 4.01 61.50 578 628 92.04 2.75 3.71 74.20 70 79 88.60
61 2011061 3.25 3.92 82.80 2.68 3.2 87.30 467 441 105.90 2.73 3.27 83.60 82.5 82.5 99.90
62 2011062 3.4 3.9 87.10 2.78 3.21 86.70 511 587 87.05 2.95 3.36 87.90 81.8 80.6 101.40
63 2011063 2.68 3.75 71.40 2.58 3.05 84.60 413 429 96.27 2.96 3.1 94.60 96.3 82.1 117.00
64 2011064 3.52 3.71 94.80 2.78 2.99 93.00 404 429 94.17 2.85 3.02 94.40 79 81.5 97.00
65 2011065 2.47 3.63 68.10 1.78 2.83 62.90 299 404 74.01 2 2.62 76.30 72.1 78.9 91.30
66 2011066 2.94 4.77 61.70 2.42 3.77 64.20 632 617 102.43 2.38 3.53 67.50 82.3 79 104.80
67 2011067 2.55 3.8 67.10 2.11 3.07 68.60 601 583 103.09 2.13 3.11 68.60 82.7 79.6 104.00
68 2011068 3.11 3.03 102.70 1.9 2.4 79.10 267 399 66.92 3.35 2.49 134.60 61.1 80 76.40
69 2011069 3.76 3.47 108.30 2.78 2.73 101.90 421 556 75.72 2.23 2.59 86.00 73.9 77.7 95.10
70 2011070 2.91 3.42 85.20 1.85 2.71 68.20 287 411 69.83 3.59 2.7 132.80 63.6 80.2 79.30
71 2011071 3.19 3.68 86.60 2.5 2.84 88.20 433 552 78.44 3.6 2.54 142.00 78.4 76.7 102.20
72 2011072 3.63 3.39 107.10 2.21 2.66 83.20 467 550 84.91 2.9 2.51 115.40 60.9 77.7 78.50
73 2011073 3.17 3.37 94.10 2.21 2.67 82.60 334 410 81.46 1.55 2.68 57.80 69.7 80.2 86.90
74 2011074 3.32 3.53 94.00 1.52 2.75 55.20 475 554 85.74 1.32 2.56 51.60 45.8 77.3 59.20
75 2011075 3.17 3.45 92.00 1.85 2.7 68.50 429 553 77.58 2.04 2.54 80.20 58.4 77.5 75.00
Master chart showing spirometric values of control group
Sl no 
Study ID 
No. of 
controls
Rec      
FVC 
Pred 
FVC 
% Pred 
FVC
Rec 
FEV1 
Pred 
FEV1 
% Pred 
FEV1
Rec           
PEF 
Pred       
PEF 
% Pred 
PEF
Rec 
FEF25-75
Pred 
FEF25-75 
% Pred 
FEF25-75
Rec 
FEV1/FVC
Pred 
FEV1/FVC
% Pred 
FEV1/FVC
76 2011076 3.22 3.1 103.80 2.78 2.49 111.60 349 408 85.54 2.84 2.64 107.40 86.3 80.8 106.80
77 2011077 3.22 3.83 84.10 1.98 2.96 66.90 398 561 70.94 1.94 2.65 73.20 61.5 76.9 80.00
78 2011078 3.25 3.34 97.30 2.39 2.66 89.80 387 411 94.16 2.52 2.7 93.40 73.5 80.4 91.50
79 2011079 3.43 3.34 102.80 2.21 2.59 85.20 411 543 75.69 2.65 2.41 109.90 64.4 77.1 83.60
80 2011080 3.22 4.7 68.50 2.89 3.79 76.30 643 620 103.71 2.52 3.72 67.70 89.8 80.2 111.90
81 2011081 3.56 3.91 91.10 2.78 3.14 88.40 369 434 85.02 2.63 3.11 84.50 78.1 81.5 95.90
82 2011082 3.17 4.5 70.50 2.76 3.62 76.20 651 612 106.37 3.52 3.57 98.60 87.1 80 108.80
83 2011083 3.3 3.62 91.10 2.63 2.96 88.90 421 432 97.45 2.63 3.1 85.00 79.7 82.3 96.80
84 2011084 3.17 4.44 71.40 2.4 3.49 69.60 586 600 97.67 2.58 3.24 79.70 76.7 78.4 97.80
85 2011085 3.32 4.56 72.80 2.34 3.63 64.80 609 612 99.51 2.67 3.49 76.60 70.5 79.4 88.80
86 2011086 3.17 2.98 106.50 2.39 2.38 100.50 356 401 88.78 1.85 2.52 73.30 75.4 80.4 93.80
87 2011087 3.22 4.45 72.30 2.42 3.53 68.50 543 606 89.60 2.58 3.35 76.90 75.2 79 95.20
88 2011088 3.12 4.65 67.00 2.68 3.66 73.10 576 610 94.43 2.92 3.39 86.10 85.9 78.6 109.30
89 2011089 3.37 3.77 89.30 2.81 3 93.80 377 422 89.34 3.6 2.9 124.10 83.4 80.4 103.70
90 2011090 3.45 4.53 76.20 2.7 3.52 76.80 432 594 72.73 2.75 3.14 87.50 78 77.4 100.90
91 2011091 2.79 3.14 88.90 1.9 2.49 76.20 311 404 76.98 2.73 2.57 106.20 68.1 80.2 84.90
92 2011092 3.22 3.59 89.70 2.18 2.84 76.90 301 413 72.88 2.95 2.75 107.10 67.7 80 84.70
93 2011093 3.25 4.26 76.40 1.85 3.35 55.20 485 594 81.65 3.52 3.14 112.30 56.9 78.4 72.60
94 2011094 3.4 4.71 72.20 2.5 3.67 68.10 499 605 82.48 2.63 3.31 79.40 73.5 77.9 94.30
95 2011095 3.01 3.97 75.90 1.82 3.12 58.30 355 420 84.52 2.58 2.9 88.90 60.5 79.8 75.80
96 2011096 2.91 3.98 73.10 2.06 3.04 67.70 391 557 70.20 2.34 2.64 88.80 70.8 76.3 92.80
97 2011097 3.19 4 79.80 1.52 3.24 46.90 457 441 103.63 3.35 3.24 103.30 47.6 82.1 58.00
98 2011098 3.63 4.5 80.60 2.39 3.54 67.50 584 603 96.85 3.23 3.27 98.70 65.8 78.4 84.00
99 2011099 3.31 3.98 83.30 2.41 3.15 76.50 345 426 80.99 2.63 3 87.80 72.8 80.4 90.60
100 2011100 3.09 3.91 79.10 2.06 3.09 66.90 299 423 70.69 1.58 2.93 53.90 66.7 80.2 83.10
Master Chart showing basic characters of case group 
Sl no 
Study ID 
No. of 
cases age sex ht in cms wt in kgs BMI
Duration 
of Type-
2DM Rx BP complications fundus FBS mg/dl 
PPBS 
mg/dl Hb1Ac %
1 2011001 41 Male 158 52 20.83 8 OHA 130/90 - - 188 278 7.1
2 2011002 44 Female 151 56 24.56 6 OHA 142/96 - - 145 290 8
3 2011003 42 Male 153 44 18.80 8 OHA 120/70 - - 226 276 9.1
4 2011004 44 Female 162 67 25.53 6 OHA 144/88 - - 178 321 6.4
5 2011005 44 Male 165 71 26.08 5 OHA 136/84 - - 258 390 8
6 2011006 57 Female 158 53 21.23 11 Ins 160/94 N,DN PDR 287 398 8.9
7 2011007 48 Female 155 59 24.56 9 OHA 130/80 DN NPDR 199 298 7.3
8 2011008 49 Female 157 50 20.28 9 OHA 120/80 - - 286 378 8.1
9 2011009 47 Male 159 68 26.90 8 OHA 148/88 - NPDR 282 333 7.4
10 2011010 55 Female 157 65 26.37 9 Ins 154/86 DN PDR 226 298 6.9
11 2011011 53 Male 166 78 28.31 11 OHA 148/78 - - 245 398 9.1
12 2011012 58 Female 163 53 19.95 12 Ins 158/86 - - 212 323 9.5
13 2011013 47 Male 171 80 27.36 7 OHA 140/90 - - 146 276 5.9
14 2011014 41 Female 169 69 24.16 9 Ins 130/80 DN PDR 123 187 6.5
15 2011015 42 Male 169 73 25.56 8 OHA 134/88 DN NPDR 167 212 7.1
16 2011016 47 Male 172 79 26.70 7 OHA 138/80 - - 164 202 6.9
17 2011017 42 Female 169 69 24.16 6 OHA 116/74 - - 187 289 7.4
18 2011018 44 Male 171 74 25.31 7 OHA 160/90 - - 217 264 8
19 2011019 39 Male 165 69 25.34 5 OHA 128/82 - - 114 172 6.6
20 2011020 41 Female 169 64 22.41 6 OHA 126/80 - - 162 254 7
21 2011021 46 Male 168 76 26.93 9 OHA 130/90 - - 234 267 6.9
22 2011022 52 Female 162 68 25.91 9 OHA 138/88 - - 165 243 9.2
23 2011023 49 Male 172 82 27.72 8 OHA 140/90 - NPDR 239 308 7.2
24 2011024 44 Male 177 73 23.30 6 OHA 144/84 - - 112 188 6.8
25 2011025 45 Female 169 61 21.36 7 OHA 130/80 - - 141 198 7
Master Chart showing basic characters of case group 
Sl no 
Study ID 
No. of 
cases age sex ht in cms wt in kgs BMI
Duration 
of Type-
2DM Rx BP complications fundus FBS mg/dl 
PPBS 
mg/dl Hb1Ac %
26 2011026 49 Male 178 81 25.56 5 OHA 150/90 - - 115 226 7.9
27 2011027 48 Male 166 66 23.95 6 OHA 140/94 - - 223 367 8.3
28 2011028 49 Female 154 57 24.03 8 OHA 130/90 - NPDR 187 310 8
29 2011029 45 Male 158 61 24.44 6 OHA 132/90 - - 167 192 6.1
30 2011030 57 Female 162 59 22.48 12 Ins 150/94 N,DN PDR 275 358 9.4
31 2011031 49 Female 169 70 24.51 10 Ins 166/100 DN PDR 216 198 7.2
32 2011032 51 Male 173 81 27.06 7 OHA 146/90 - - 198 343 8.2
33 2011033 44 Female 166 65 23.59 9 OHA 154/90 - - 246 270 6.6
34 2011034 54 Male 169 67 23.46 7 OHA 126/78 - - 112 195 6.9
35 2011035 51 Male 168 78 27.64 10 Ins 170/90 N,DN PDR 128 198 9.2
36 2011036 47 Female 169 68 23.81 9 OHA 116/70 - - 155 184 7.2
37 2011037 49 Male 163 66 24.84 7 OHA 142/90 - - 181 229 6
38 2011038 55 Female 161 54 20.83 9 OHA 158/94 - - 182 233 7.1
39 2011039 53 Male 165 73 26.81 8 OHA 154/90 - - 169 201 7.3
40 2011040 51 Female 168 69 24.45 6 OHA 130/90 - - 129 160 6.1
41 2011041 48 Male 166 70 25.40 11 OHA 126/78 - - 143 245 9.1
42 2011042 41 Male 168 59 20.90 5 OHA 120/80 - - 158 212 6.9
43 2011043 48 Female 161 60 23.15 8 OHA 130/90 - NPDR 190 301 7.8
44 2011044 51 Male 169 66 23.11 9 Ins 150/88 N,DN PDR 221 299 7.9
45 2011045 41 Male 165 61 22.41 6 OHA 128/86 - - 186 221 7
46 2011046 41 Female 159 60 23.73 7 OHA 110/76 - - 221 298 7.5
47 2011047 44 Male 169 70 24.51 6 OHA 124/80 - - 121 244 6.2
48 2011048 41 Female 160 67 26.17 9 Ins 130/80 DN NPDR 276 312 8
49 2011049 49 Female 163 64 24.09 8 OHA 140/90 DN NPDR 298 267 7.3
50 2011050 51 Male 171 70 23.94 10 Ins 144/88 N,DN NPDR 156 254 9.3
Master Chart showing spirometric values of case group 
Sl no 
Study ID 
No. of 
cases
Rec      
FVC 
Pred 
FVC 
% Pred 
FVC
Rec 
FEV1 
Pred 
FEV1 
% Pred 
FEV1
Rec           
PEF 
Pred       
PEF 
% Pred 
PEF
Rec 
FEF25-75
Pred 
FEF25-75 
% Pred 
FEF25-75
Rec 
FEV1/FVC
Pred 
FEV1/FVC
% Pred 
FEV1/FVC
1 2011001 2.92 4.03 97.20 1.88 3.25 57.90 377 593 63.58 1.74 3.24 53.80 64.4 79.6 80.90
2 2011002 2.57 3.11 82.80 1.66 2.52 65.90 312 412 75.73 2.13 2.73 77.90 64.6 81.5 79.00
3 2011003 2.67 3.72 85.10 1.56 3 51.90 433 579 74.78 1.54 3.02 54.20 58.4 79.4 73.60
4 2011004 3.63 3.62 100.40 2.55 2.92 87.50 354 426 83.10 3.83 2.97 128.80 70.2 81.5 86.20
5 2011005 2.7 4.39 61.50 1.83 3.49 52.50 456 604 75.50 3.13 3.32 94.30 67.8 79 85.80
6 2011006 1.24 3.17 57.00 1.85 2.47 75.00 256 443 57.79 1.7 2.7 113.70 54 78.7 64.00
7 2011007 2.24 3.22 69.50 1.78 2.57 69.10 335 409 81.91 2.04 2.37 76.40 67.5 80.6 78.60
8 2011008 2.3 3.44 66.80 1.51 2.83 53.30 284 428 66.36 2.04 3.04 67.10 65.7 82.5 77.60
9 2011009 2.68 3.96 67.80 1.95 3.13 62.40 579 582 99.48 3.45 2.97 116.20 62.8 78.4 72.90
10 2011010 2.32 3.17 84.80 1.72 2.48 69.30 205 395 51.90 2.62 2.44 107.60 51.8 79.1 65.50
11 2011011 1.45 4.22 48.00 1.45 3.26 50.50 442 578 76.47 2.07 2.9 78.20 59.2 77.1 76.70
12 2011012 1.12 3.38 52.20 1.58 2.63 60.20 230 394 58.38 2.04 2.44 83.40 58.2 78.5 72.50
13 2011013 2.48 4.69 52.80 1.43 3.68 38.80 558 609 91.63 2.27 3.38 67.20 57.7 78.4 73.60
14 2011014 2.78 4 69.50 1.85 3.24 57.10 256 440 58.18 2.86 3.24 88.20 66.5 82.1 81.10
15 2011015 3.09 4.68 66.00 2.01 3.7 53.90 461 617 74.72 3.11 3.56 87.40 65 79.4 81.90
16 2011016 3.14 4.76 66.00 2.08 3.73 55.70 577 607 95.06 3.68 3.41 107.80 60.2 78.4 74.50
17 2011017 2.08 3.99 52.20 2.18 3.22 66.60 424 439 96.58 2.65 3.21 82.60 56.7 81.9 69.30
18 2011018 2.58 4.77 54.10 1.46 3.77 38.70 324 617 52.51 2.7 3.53 76.50 56.6 79 71.70
19 2011019 2.55 4.5 76.40 1.52 3.62 52.00 609 612 99.51 2.7 3.57 75.70 59.7 80 74.60
20 2011020 2.44 4 61.00 1.8 3.24 55.50 435 440 98.86 3.04 3.24 62.90 73.8 82.1 89.90
21 2011021 2.03 4.53 44.80 1.25 3.57 35.00 499 605 82.48 2.45 3.32 73.70 61.6 78.6 78.40
22 2011022 2.74 3.64 75.20 1.72 2.96 58.20 451 430 104.88 2.99 3.05 98.10 62.8 81.9 76.70
23 2011023 2.44 4.71 51.80 1.65 3.67 44.90 357 605 59.01 1.87 3.31 56.40 67.6 77.9 86.80
24 2011024 3.01 5.15 70.40 1.78 4.06 53.80 458 630 72.70 2.56 3.74 41.70 59.1 79 78.90
25 2011025 2.34 3.94 59.30 1.48 3.16 46.80 487 433 112.47 2.11 3.1 68.10 63.2 81.2 77.80
Master Chart showing spirometric values of case group 
Sl no 
Study ID 
No. of 
cases
Rec      
FVC 
Pred 
FVC 
% Pred 
FVC
Rec 
FEV1 
Pred 
FEV1 
% Pred 
FEV1
Rec           
PEF 
Pred       
PEF 
% Pred 
PEF
Rec 
FEF25-75
Pred 
FEF25-75 
% Pred 
FEF25-75
Rec 
FEV1/FVC
Pred 
FEV1/FVC
% Pred 
FEV1/FVC
26 2011026 2.48 5.1 68.30 1.49 3.97 57.50 524 617 84.93 2.68 3.53 47.60 60.1 77.9 77.10
27 2011027 2.77 4.35 63.60 1.7 3.42 49.80 542 595 91.09 2.42 3.15 76.70 61.4 78.1 78.50
28 2011028 3.27 3.16 103.60 1.8 2.52 71.50 387 406 95.32 2.67 2.61 102.30 55 80.4 68.50
29 2011029 4.02 3.94 101.90 2.48 3.14 79.00 558 585 95.38 2.11 3.04 69.50 61.7 78.8 78.30
30 2011030 1.33 3.36 58.30 1.71 2.61 65.40 223 396 56.31 2.19 2.46 88.90 60.5 78.7 72.60
31 2011031 1.73 3.87 67.00 1.88 3.07 61.20 261 424 61.56 1.63 2.95 55.30 55.8 80.4 69.40
32 2011032 2.24 4.72 47.50 1.18 3.66 32.20 329 600 54.83 2.15 3.25 66.20 52.7 77.5 69.70
33 2011033 2.35 3.81 61.70 1.36 3.07 44.30 398 431 92.34 2.47 3.07 80.60 57.9 81.5 71.00
34 2011034 2.41 4.38 65.70 1.35 3.37 60.00 278 580 47.93 2.42 2.96 81.80 56 76.9 77.80
35 2011035 2.33 4.4 52.90 1.43 3.42 41.80 334 589 56.71 2.31 3.07 75.20 61.4 77.5 79.20
36 2011036 2.04 3.91 54.20 1.17 3 39.00 286 429 66.67 1.65 2.95 55.90 57.4 80.8 71.00
37 2011037 2.38 4.15 57.40 1.38 3.25 42.50 470 585 80.34 2.03 3 67.60 58 77.9 74.40
38 2011038 2.53 3.36 75.40 1.69 2.63 64.30 215 400 53.75 1.94 2.52 76.80 63.8 79.1 74.40
39 2011039 2.1 4.16 50.50 1.9 3.22 64.20 440 576 76.39 2.13 2.87 74.20 52.4 77.1 67.90
40 2011040 2.33 3.79 61.60 1.34 2.99 44.80 254 418 60.77 1.78 2.85 62.50 57.5 80 71.90
41 2011041 1.25 4.35 44.80 1.12 3.42 32.80 421 595 70.76 1.2 3.15 38.10 57.4 78.1 73.50
42 2011042 2.88 4.64 62.00 1.84 3.71 49.60 603 616 97.89 2.28 3.57 63.80 63.9 79.6 80.30
43 2011043 3.3 3.5 94.20 2.44 2.79 87.40 312 417 74.82 3.03 2.8 108.10 65.9 80.6 71.70
44 2011044 2.3 4.46 51.50 1.45 3.57 41.80 377 585 64.44 1.94 3.11 62.40 63 77.5 71.30
45 2011045 4.1 4.46 92.00 2.7 3.57 75.70 672 609 110.34 3 3.47 57.70 65.9 79.6 82.70
46 2011046 3.13 3.51 89.10 2.62 2.87 91.40 359 428 83.88 2.74 3.02 90.90 73.1 82.1 82.00
47 2011047 2.38 4.64 51.30 2.42 3.67 58.70 588 613 95.92 2.13 3.46 61.60 59.7 79 75.50
48 2011048 2.63 3.45 76.10 1.55 2.76 56.20 352 429 82.05 2.54 2.78 91.40 58.9 80.6 73.10
49 2011049 2.5 3.58 69.80 1.77 2.84 62.20 368 417 88.25 2.83 2.81 100.80 65.8 80.4 78.80
50 2011050 1.62 4.59 61.90 1.7 3.56 47.70 316 596 53.02 2.78 3.18 87.50 51.5 77.5 66.40
 LIST OF ABBREVIATIONS 
 
DM Diabetes Mellitus 
ADA  American Diabetes Association  
FVC  Forced vital capacity  
FEV1  Forced expiratory volume in 1 seconds  
FEV1/FVC%  FEV1 as percentage of FVC  
FEF25-75%  Forced mid-expiratory flow  
FBS  Fasting blood glucose level  
HbA1c  Glycated hemoglobin  
PEF  Peak expiratory flow  
PPBS  Post prandial blood glucose level  
PFT  Pulmonary function tests  
IDDM.  Insulin dependent diabetes mellitus  
NIDDM  Non-Insulin dependent diabetes mellitus  
BMI Body mass index 
SD Standard deviation 
BTPS Body temperature pressure saturated 
 
